Research Progress of Oral BCL-2 Inhibitor Venetoclax in the Treatment of Non-Hodgkin's Lymphoma --Review.
10.19746/j.cnki.issn.1009-2137.2022.05.051
- Author:
Meng-Qi GUO
1
;
Xing-Yu LUO
1
;
Hui-Yang WU
1
;
Yu-Xian HUANG
2
,
3
Author Information
1. Department of Hematology, Zhu Jiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China.
2. Department of Hematology, Zhu Jiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China,E-mail: hyx6610@
3. com.
- Publication Type:Review
- Keywords:
non-Hodgkin′s lymphoma;
targeted therapy;
venetoclax
- MeSH:
Aged;
Antineoplastic Agents/therapeutic use*;
Apoptosis Regulatory Proteins;
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use*;
Hematologic Neoplasms/drug therapy*;
Humans;
Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy*;
Lymphoma, B-Cell;
Lymphoma, Non-Hodgkin/drug therapy*;
Proto-Oncogene Proteins c-bcl-2/metabolism*;
Sulfonamides
- From:
Journal of Experimental Hematology
2022;30(5):1622-1626
- CountryChina
- Language:Chinese
-
Abstract:
Abnormal cell apoptosis is closely related to the occurrence of hematologic tumors, B-cell lymphoma-2 (BCL-2), as a key anti-apoptotic protein in intrinsic programmed cell death, has become a hot spot in the treatment of hematologic tumors in recent years. Venetoclax is an oral small-molecule selective BCL-2 inhibitor approved by the Food and Drug Administration (FDA） for the treatment of chronic lymphocytic leukemia (CLL) patients or small lymphocytic lymphoma (SLL) patients and for the treatment of elderly acute myeloid leukemia (AML) patients that is not suitable for aggressive chemotherapy. In addition, it also showed a promising clinical application in treatment of non-Hodgkin's lymphoma (NHL) patients, which is a new expansion of the clinical indications for venetoclax. In this review, the role of BCL-2 protein family played in the regulation of NHL cell apoptosis, the development of BCL-2 inhibitors and the recent research progress of venetoclax in the treatment of NHL are reviewed.
